> Back to EJC

2016 editions

  • December 2016
    Joao Incio on mechanisms to explain why obesity promotes cancer.
  • November 2016
    Mike Stratton on how mutational changes in a cancer genome can point to the cause of the cancer.
  • October 2016
    Ruth Muschel on a new target for treatments for colorectal cancer.
  • September 2016
    Freddie Hamdy on the effectiveness of treatments for prostate cancer.
  • August 2016
    Moshe Oren discusses the effects of the microenvironment on cancer cells.
  • July 2016
    Richard Gilbertson on the 'bad luck hypothesis' for the cause of cancer.
  • June 2016
    Key advances in clinical trials.
  • May 2016
    Mark Lemmon on the underlying biochemistry of cancer.
  • April 2016
    Roger Stupp on using alternating electric fields as treatment.
  • March 2016
    Charlotte Vrinten on public perception of deaths from cancer.
  • February 2016
    Guillermo Garcia-Manero on myelodysplastic syndromes (MDS).
  • December 2015/January 2016
    Nazneen Rahman on germline genetic screening in ovarian cancer.

> All 2015 Editions

> All 2014 Editions

> All 2013 Editions

> All 2012 Editions

> All 2011 Editions

EJC News Focus – November 2013

Loading EJC News Focus video

Highlights of European Cancer Congress

"Astonishing" results with immunotherapy in a range of hard to treat cancers were the highlight of the Congress (27 September – 1st October, 2013) for Martine Piccart (ESMO). For Vincenzo Valentini (ESTRO), it was the new perception that that local treatment with radiation therapy could have an impact on systemic disease. Graeme Poston (ESSO) picked out the training of young surgical oncologists, which may now last only 6,000 hours, compared with up to 40,000 hours for previous generations of surgeons. How can the profession ensure that they are safe?

In this month's EJC News Focus, Helen Saul meets the Presidents of various cancer societies, including Moshe Oren (EACR), Birgitte Grube (EONS) and Cornelis van de Velde (ECCO), and asks for their take-home messages from the European Cancer Congress.